31 commercial payer policies list J2329. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
31 policies from 18 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (ublituximab-xiij)Effective 05/01/2023 - 04/30/2024 | May 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Briumvi (ublituximab-xiiy) Intravenous Injection | Not recorded | Prior auth requiredInferred from policy title |
| Briumvi (ublituximab-xiiy) Intravenous InjectionEffective 05/01/2024 - 04/30/2025 | May 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Briumvi (ublituximab-xiiy) Intravenous InjectionEffective 05/01/2025 - 04/30/2026 | May 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (Ublituximab-Xiiy) | Jan 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Briumvi (Ublituximab-Xiiy) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Briumvi (Ublituximab-Xiiy) – Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Ublituximab-xiiy (Briumvi ) for intravenous use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Ublituximab-xiiy (Briumvi) for intravenous use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Ublituximab-xiiy | May 1, 2026 | Covered |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Ublituximab-xiiy | May 1, 2026 | Covered |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Ublituximab-xiiy | May 1, 2026 | Covered |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Ublituximab-xiiy | May 1, 2026 | Covered |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Ublituximab-xiiy (Briumvi ) for intravenous use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Ublituximab-xiiy (Briumvi) for intravenous use | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (Ublituximab-Xiiy) | Jan 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Ublituximab-xiiy (e.g., Briumvi) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Multiple Sclerosis Products:(Ocrelizumab [Ocrevus], Ocrelizumab and Hyaluronidase-ocsq [Ocrevus Zunovo], Ublituximab-xiiy [Briumvi]) | Feb 10, 2026 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (ublituximab) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Ublituximab-xiiy (Briumvi); CP.PHAR.621 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Ublituximab-xiiy (Briumvi) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| 00838 ublituximab (Briumvi) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (ublituximab-xiiy) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (ublituximab) (PG134, Ver. 6) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2329 |
|---|---|---|
| Briumvi (Ublituximab-Xiiy) | Jan 1, 2026 | Covered |